SLGL News and Press, Sol-Gel Technologies Ltd. From 05/23/19

NESS ZIONA, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...

Sol-Gel Technologies (NASDAQ: SLGL ): Q1 GAAP EPS of -$0.30 beats by $0.37 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Top-line results from Phase III Epsolay ® and TWIN trials remain on track; mid-2019 and 4Q19, respectfully Reports top-line generic product revenues of $6.3 million NESS ZIONA, Israel, May 22, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Ge...

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top-line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company&#x...

Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay ® and TWIN, potentially best-in-class papulopustular rosacea and acne vulgaris topical medications Recent approval of Perrigo's generic acyclovir cream, 5%, has already prov...

NESS ZIONA, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, ...

DUBLIN , Feb. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Zovirax® Cream, 5% (acyclovir cream, 5%) deve...

First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of approximately 840 subjects Top-line data anticipated by the end of 2019 NESS ZIONA, Israel, Dec. 17, 2018 (GLOBE...

NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...

NESS ZIONA, Israel, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...